Lv11
98 积分 2023-10-08 加入
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
6小时前
待确认
Tumor Antigen Escape from CAR T-cell Therapy
25天前
已完结
A Phase 1 Study of KITE-753 or KITE-363 in Patients with Relapsed/Refractory B-cell Lymphoma: Initial Safety and Preliminary Efficacy of KITE-753 and Updated Results of KITE-363
1个月前
已关闭
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma
1个月前
已完结
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
1个月前
已完结
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
1个月前
已完结
骨髓增生异常肿瘤诊断与治疗中国指南（2026年版）
1个月前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
6个月前
已完结
Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy
1年前
已完结
皖公网安备34019202002308
